Naturalnano Inc. (OTC: NNAN) gained 11.11% to $0.0010, with strong volume of 38.63 million shares traded. Shares of the material science company were boosted after the announcement of an exclusive joint development and supply deal with Sparta Armor for improved vehicle and body armor products. Based in Pittsford, N.Y., NaturalNano focuses on the development and commercialization of advanced nanocomposites.
Clean Coal Technologies Inc. (PINK: CCTC) jumped 22.81% to $0.0350, above-average volume of 9.23 million shares. Headquartered in New York City, NY, Clean Coal Technologies owns a patented process technology to convert coal into a cleaner burning fuel source.
Mammoth Energy Group Inc. (PINK: MMTE) gained 25.00% to $0.0005, on high volume of 53.47 million shares. Mammoth Energy Group is focused on acquiring, developing and operating strategic mining energy reserves in locations throughout the world.
Fox Petroleum Inc. (PINK: FXPT) advanced 20.00% to $0.0120, with volume of 5.36 million shares traded. Fox Petroleum, a development stage company, engages in the identification, exploration, acquisition, and development of prospective oil and gas properties. The company on Tuesday filed its latest quarterly report with the SEC.
AMR Corp. (PINK: AAMRQ) rose 3.23% to $0.415, on volume of 6.90 million shares. AMR, through its principal subsidiary, American Airlines Inc., provides scheduled jet service to approximately 160 destinations throughout North America, the Caribbean, Latin America, Europe, and Asia.
Generex Biotechnology Corp. (OTC: GNBT) dropped 29.50% to $0.184, on above-average volume of 11.85 million shares. It has a 52-week range of $0.08 – $0.32. Generex subsidiary Antigen Express has recently outlined advantages of the Ii-Key immunotherapeutic vaccine, following positive interim data from its Phase 2b breast cancer trial announced last month at the San Antonio Breast Cancer Symposium.
MultiCell Technologies Inc. (OTC: MCET) slipped 9.09% to $0.0050, with volume of 7.86 million shares traded. MultiCell Technologies, together with its majority owned subsidiary Xenogenics, engages in the development of novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, cancer, cardiac and hepatic disease and some types of autoimmune diseases.
For the latest updates on the stock market, visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
No comments:
Post a Comment